Dermatol. praxi. 2017;11(3):142-144 [Onkologie. 2017:11(2):92-95]

Case report of a patient with metastatic malignant melanoma treated with pembrolizumab

MUDr. Alena Fialová, doc. MUDr. Monika Arenbergerová, Ph.D.
Dermatovenerologická klinika, Fakultní nemocnice Královské Vinohrady v Praze

Background: The prognosis of patients with malignant melanoma is poor. Treatment of pembrolizumab leads to prolonged life.Case: The patient with metastatic malignant melanoma stage IV with negative BRAF mutation treated with pembrolizumab witha complete response.

Conclusion: Our case report highlights the good responses at treatment of pembrolizumab.

Keywords: report, metastatic malignant melanoma, immunotherapy, checkpoint inhibitors, pembrolizumab, radiotherapy

Published: October 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Fialová A, Arenbergerová M. Case report of a patient with metastatic malignant melanoma treated with pembrolizumab. Dermatol. praxi. 2017;11(3):142-144.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors Adv Immunol 2006; 90: 51-81. Go to original source... Go to PubMed...
    2. Finn OJ. Immuno-oncology: understanding the function and dysfunction of th immune system in cancer. Ann Oncol 2012; 23(Suppl. 8):viii6-viiii9. Go to original source... Go to PubMed...
    3. Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 2015; 16: 908. Go to original source... Go to PubMed...
    4. Hamid O, Puzanov I, Dummer R, et al. Final overall survival for KEYNOTE-002: pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma. Abstract 11070, presented at the 2016 European Society for Medical Oncology meeting. Go to original source...
    5. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 2015; 372: 2521. Go to original source... Go to PubMed...
    6. Schacter J, Ribas A, Ling GV, et al. Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival analysis of KEYNOTE-006. Abstract 9504, American Society of Clinical Oncology 2016 annual meeting. Go to original source...
    7. Daud AI, Wolchok JD, Robert C, et al. Programmed death-ligand 1 expression in response to the anti-programmed death 1 antibody pembrolizumab in melanoma. J Clin Oncol 2016. Go to original source... Go to PubMed...
    8. Changes in blood eosinophilia during anti-PD1 therapy as a predictor of long term disease control in metastatic melanoma. 2015 ASCO Annual Meeting Poster Session, J Clin Oncol 33, 2015; (Suppl; abstr 9069).
    9. Hua C, Boussemart L, Mateus C, et al. Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab. JAMA Dermatol. 2016; 152(1): 45-51. doi: 10.1001/jamadermatol.2015.2707. PubMed PMID: 26501224. Go to original source... Go to PubMed...
    10. Esposito A, Criscitiello C, Curigliano G. Immune checkpoint inhibitors with radiotherapy and locoregional treatment: synergism and potential clinical implications. Curr Opin Oncol. 2015; 27(6): 445-451. Go to original source... Go to PubMed...

    Return to the content


    Dermatology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.